Trade name : Crixivan
Active ingredient : Indinavir
Strength availability : 400mg
Manufactured by : Cipla
Package : 30 tablets
Crixivan capsule which belongs to a human immunodeficiency protease inhibitor. Crixivan is a type of antiviral drug that blocks HIV from replication in our body Crixivan is not used for HIV and Aids and it is prescription drug sold under the supervision of doctor
Cirixivan primarily indicated with combination of other antiretroviral for the treatment of HIV infection.
The drug uses is based on two clinical trials essentially foe 1 year duration which describes :
Reduction in the risk of AIDS-defining illness or death
A prolonged elimination of HIV RNA.
How the drug administrated and dosage
The prescribed dosage for adult is Crixivan is 800mg administer as two 400mg capsules given orally every 8 hours in concomitant use with other antiretrovirals to treat HIV infections. Combination with Ritonavir then 800mg plus Ritonavir 100mg to 200mg twice a day The patients taking Crixivan must be take intervals of 8 hours Crixivan should given without food with water 1 hour before or 2 hours after meal. It can be also taken with other liquids such as skim milk,juice,coffee or tea or with a light meal The patients ensure adequate hydration its prescribed adults drinks at least 1.5 liters of liquids during the course of 24 hours
MECHANISM OF ACTION
An enzyme HIV-1 protease is necessary for the proteolytic gap of the viral polyprotein precursors coalesce to the individual functional proteins create in HIV-1 infectious. Indinavir interpolated to the protease active site and prevents the activity of the enzyme. This hindrance prevents cleavage of the viral polyproteins causing in the formation of immature non-infectious viral particles.
Absorption : fastly absorbed, time to maximum plasma protein is 0.8±0.3 hrs
Distribution : bounding of human plasma protein of Crixivan is 60%
Metabolism : In hepatic is metabolized
Elimination : < 20% of indinavir is eliminated in the urine unchanged. Half life of Crixivan is 1.8 (±0.4) hours.
Concomitant use with drugs that induce CYP3A4 activity will raises the clearance of indinavir, reports in lowering of plasma concentrations of indinavir Interaction of indinavir with drugs metabolized by CYP3A4 wills increases plasma concentration of the other drugs.
Crixivan contraindicated in Hypersensitivity to any of its components Inhibition of CYP3A4
Hemolytic Anemia :
Acute hemolytic anemia includes cases result in death. Hence stop the course of Crixivan capsules
Hepatitis : The patient having hepatitis has been treated with Crixivan will leads to hepatic failure and death
Nephrolithiasis/ urolithiasis : Nephrolithiasis events cumulative frequency increase with increasing exposure of Crixivan hence risk over time remains the same
Fat redistribution : The mechanism and long term consequence of these events are currently unknown. A causal relationship has not been established.
If patients missed a dose then have the drug while you remember before next dose timing or skip the missed dose and follow regular schedule Please consult with the doctor
More common :
Blood in urine, Just below ribs severe back pain. Less common :
Abdominal pain, Chills, Loss of appetite, Dizziness, Fever, Headache, Unpleasant breath odor, Vomiting of blood, Rare cases, Confusion, dehydration, dry or itchy skin, fruity mouth odor, increased hunger, increased urination, pale skin, troubled breathing with exertion, unusual bleeding or bruising, unusual tiredness or weakness, vomiting, weight loss.